Delivery Order SPE2DB20D1109-SPE2DB25FP84Y
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Olopatadine HCL 0.1% eye drops (5ml) with a ceiling value of $3,491.87. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is due for completion by September 26, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This award represents a routine...
- The Defense Logistics Agency awarded a $1,434.04 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ml quantities. This firm fixed-price contract, with an ultimate completion date of August 25, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting open competition among qualified pharmaceutical vendors....
- The Defense Logistics Agency awarded a delivery order valued at $2,046.81 to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ml quantities. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of September 26, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its Corporate Office location in Conshohocken, PA....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Olopatadine HCL 0.1% eye drops (5 mL units) with a ceiling value of $1,148.94. This firm fixed-price delivery order is not set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. The pharmaceutical products will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,708.86 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops in 5ml units. This firm fixed price delivery order, awarded on August 8, 2025, is set to be completed by August 11, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The contract represents a non-set-aside competitive award, demonstrating AmerisourceBergen's capability to fulfill...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% Eye Drops (5ML) with a ceiling value of $2,789.33. The contract, which is a firm fixed-price delivery order, was awarded on May 9, 2025, with an ultimate completion date of May 12, 2025. This award does not include a set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,380.55 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL units). This firm fixed price, competitively awarded contract was executed on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract represents a non-set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,757.44 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops (5 mL) under a firm fixed-price contract. The award, issued on May 30, 2025, with an ultimate completion date of June 2, 2025, represents a non-competitive delivery order with no set-aside designation. Performance of this order will be executed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a Delivery Order contract valued at $2,228.42 to AmerisourceBergen Drug Corp for the supply of Olopatadine HCL 0.1% eye drops in 5ml units. The contract was competitively awarded without set-aside restrictions and carries a firm fixed price structure, with an ultimate completion date of August 15, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery order...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olopatadine HCl 0.1% eye drops. The contract has a ceiling value of $1,034.90 and a completion date of June 24, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp also holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D1109Indefinite Delivery Contract
- SPE2DB20D1109-SPE2DB25FP84YDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Olopatadine HCL 0.1% eye drops in 5ML units, with a ceiling value of $1,310.70. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle extending through December 2026. As a prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen provides a broad spectrum of pharmaceutical products and medical supplies to support military and federal healthcare systems globally. The DLA continues to leverage this prime vendor relationship to fulfill critical medical procurement needs, with plans underway to establish next-generation pharmaceutical prime vendor contracts across multiple regions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/26/25 |